Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: WuXi PharmaTech | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: WuXi PharmaTech

Growth in the quarter was driven by Lab Services revenue (+16%) and a 59% increase in Manufacturing Services revenues.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi PharmaTech

4Q Revenues: $88.6 million (+20%)

4Q Earnings: $17.3 million (+42%)

FY Revenues: $334.1 million (+24%)

FY Earnings: $90.8 million (+72%)

Comments: Growth in the quarter was driven by Lab Services revenue (+16%) and a 59% increase in Manufacturing Services revenues. For the year, growth was driven by both China- and U.S.-based Lab Services revenue (+18%) and 95% growth in Manufacturing Services revenues. In the quarter, earnings include a 38% growth in income from continuing operations and the non-recurrence of a loss from discontinued operations in 4Q10. FY earnings include a 30% increase in operating income and a favorable change in other income (expenses).


Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters